62 results on '"Kansakar U"'
Search Results
2. Metformin treatment in hyperglycemic INOCA patients.
- Author
-
Mone P, Varzideh F, Rainone A, Kansakar U, Jankauskas SS, Salemme L, Brunese MC, Speziale G, Tesorio T, and Santulli G
- Published
- 2024
- Full Text
- View/download PDF
3. Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside.
- Author
-
Kansakar U, Nieves Garcia C, Santulli G, Gambardella J, Mone P, Jankauskas SS, and Lombardi A
- Abstract
Ketone bodies are molecules produced from fatty acids in the liver that act as energy carriers to peripheral tissues when glucose levels are low. Carbohydrate- and calorie-restricted diets, known to increase the levels of circulating ketone bodies, have attracted significant attention in recent years due to their potential health benefits in several diseases. Specifically, increasing ketones through dietary modulation has been reported to be beneficial for cardiovascular health and to improve glucose homeostasis and insulin resistance. Interestingly, although excessive production of ketones may lead to life-threatening ketoacidosis in diabetic patients, mounting evidence suggests that modest levels of ketones play adaptive and beneficial roles in pancreatic beta cells, although the exact mechanisms are still unknown. Of note, Sodium-Glucose Transporter 2 (SGLT2) inhibitors have been shown to increase the levels of beta-hydroxybutyrate (BHB), the most abundant ketone circulating in the human body, which may play a pivotal role in mediating some of their protective effects in cardiovascular health and diabetes. This systematic review provides a comprehensive overview of the scientific literature and presents an analysis of the effects of ketone bodies on cardiovascular pathophysiology and pancreatic beta cell function. The evidence from both preclinical and clinical studies indicates that exogenous ketones may have significant beneficial effects on both cardiomyocytes and pancreatic beta cells, making them intriguing candidates for potential cardioprotective therapies and to preserve beta cell function in patients with diabetes.
- Published
- 2024
- Full Text
- View/download PDF
4. Lipoprotein(a) and Cardiovascular Risk: New Insights.
- Author
-
Varzideh F, Kansakar U, and Santulli G
- Published
- 2024
- Full Text
- View/download PDF
5. Mechanistic role of mesencephalic astrocyte-derived neurotrophic factor in myocardial ischemia/reperfusion injury.
- Author
-
Varzideh F, Wang B, Qin Y, Kansakar U, Santulli G, and Jankauskas SS
- Subjects
- Animals, Humans, Apoptosis, Myocytes, Cardiac metabolism, Nerve Growth Factors metabolism, Nerve Growth Factors genetics, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, Endoplasmic Reticulum Stress, Signal Transduction
- Abstract
Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a protein crucial for cellular stress response and survival, particularly in the nervous and cardiovascular systems. Unlike traditional neurotrophic factors, MANF primarily regulates endoplasmic reticulum (ER) stress and protects cells by reducing ER stress-induced apoptosis. MANF operates both inside and outside cells, influencing key pathways like JAK/STAT and NF-κB to enhance cell survival during stress. Beyond its neuroprotective role, MANF is also vital in cardiovascular protection, mitigating damage by reducing inflammation and maintaining cellular function. Elevated MANF levels have been observed in patients experiencing myocardial infarction and murine models of ischemia-reperfusion (I/R) injury, highlighting its importance in these conditions. Overexpression of MANF in cardiomyocytes reduces ER-stress-induced cell death, while its depletion worsens this effect. Treatment with recombinant MANF (rMANF) has been shown to improve cardiac function in mice with I/R injury by decreasing infarct size and inflammation. Research also indicates that alterations in the α1-helix region of MANF can impact its structure, expression, secretion, and overall function. Given its protective effects and involvement in critical signaling pathways, MANF is being explored as a potential therapeutic target for ER stress-related diseases, including neurodegenerative disorders and cardiovascular conditions like myocardial I/R injury., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
6. The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts.
- Author
-
Varzideh F, Jankauskas SS, Jain U, Soderquist L, Densu Agyapong E, Kansakar U, and Santulli G
- Subjects
- Humans, Mitochondria, Heart drug effects, Mitochondria, Heart metabolism, Endothelin-1 metabolism, Cells, Cultured, Endothelin A Receptor Antagonists pharmacology, Endothelin Receptor Antagonists pharmacology, Oxidative Stress drug effects, Fibroblasts drug effects, Fibroblasts metabolism
- Published
- 2024
- Full Text
- View/download PDF
7. Extracellular RNA and Endothelial TLR3 Link Inflammation and Venous Thromboembolism.
- Author
-
Savino L, Savino M, Kansakar U, Dazzetti T, Varzideh F, Jankauskas SS, Mone P, and Santulli G
- Subjects
- Humans, Endothelial Cells metabolism, Endothelial Cells immunology, Endothelial Cells pathology, Endothelium, Vascular metabolism, Endothelium, Vascular physiopathology, Animals, Venous Thromboembolism genetics, Venous Thromboembolism immunology, Venous Thromboembolism blood, Toll-Like Receptor 3 genetics, Toll-Like Receptor 3 metabolism, Inflammation metabolism, Inflammation genetics
- Published
- 2024
- Full Text
- View/download PDF
8. Insights into molecular and cellular functions of the Golgi calcium/manganese-proton antiporter TMEM165.
- Author
-
Jankauskas SS, Varzideh F, Kansakar U, Al Tibi G, Densu Agyapong E, Gambardella J, and Santulli G
- Subjects
- Humans, Animals, Glycosylation, Calcium metabolism, Cation Transport Proteins metabolism, Cation Transport Proteins genetics, Congenital Disorders of Glycosylation metabolism, Congenital Disorders of Glycosylation genetics, Congenital Disorders of Glycosylation pathology, Manganese metabolism, Golgi Apparatus metabolism, Antiporters metabolism, Antiporters genetics
- Abstract
The Golgi compartment performs a number of crucial roles in the cell. However, the exact molecular mechanisms underlying these actions are not fully defined. Pathogenic mutations in genes encoding Golgi proteins may serve as an important source for expanding our knowledge. For instance, mutations in the gene encoding Transmembrane protein 165 (TMEM165) were discovered as a cause of a new type of congenital disorder of glycosylation (CDG). Comprehensive studies of TMEM165 in different model systems, including mammals, yeast, and fish uncovered the new realm of Mn
2+ homeostasis regulation. TMEM165 was shown to act as a Ca2+ /Mn2+ :H+ antiporter in the medial- and trans-Golgi network, pumping the metal ions into the Golgi lumen and protons outside. Disruption of TMEM165 antiporter activity results in defects in N- and O-glycosylation of proteins and glycosylation of lipids. Impaired glycosylation of TMEM165-CDG arises from a lack of Mn2+ within the Golgi. Nevertheless, Mn2+ insufficiency in the Golgi is compensated by the activity of the ATPase SERCA2. TMEM165 turnover has also been found to be regulated by Mn2+ cytosolic concentration. Besides causing CDG, recent investigations have demonstrated the functional involvement of TMEM165 in several other pathologies including cancer and mental health disorders. This systematic review summarizes the available information on TMEM165 molecular structure, cellular function, and its roles in health and disease., Competing Interests: Conflict of interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Santulli is an Editorial Board Member for JBC and was not involved in the editorial review or the decision to publish this article. The other authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
9. Endothelial microRNAs in INOCA patients with diabetes mellitus.
- Author
-
Ferrone M, Ciccarelli M, Varzideh F, Kansakar U, Guerra G, Cerasuolo FA, Buonaiuto A, Fiordelisi A, Venga E, Esposito M, Rainone A, Ricciardi R, Del Giudice C, Minicucci F, Tesorio T, Visco V, Iaccarino G, Gambardella J, Santulli G, and Mone P
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Diabetes Mellitus genetics, Diabetes Mellitus diagnosis, Diabetes Mellitus blood, Percutaneous Coronary Intervention adverse effects, Endothelium, Vascular metabolism, Endothelium, Vascular physiopathology, Genetic Markers, Endothelial Cells metabolism, Case-Control Studies, MicroRNAs genetics, MicroRNAs blood, MicroRNAs metabolism, Coronary Artery Disease genetics, Coronary Artery Disease blood, Circulating MicroRNA blood, Circulating MicroRNA genetics
- Abstract
Ischemia with non-obstructive coronary artery (INOCA) is a common cause of hospital admissions, leading to negative outcomes and reduced quality of life. Central to its pathophysiology is endothelial dysfunction, which contributes to myocardial ischemia despite the absence of significant coronary artery blockage. Addressing endothelial dysfunction is essential in managing INOCA to alleviate symptoms and prevent cardiovascular events. Recent studies have identified diabetes mellitus (DM) as a significant factor exacerbating INOCA complications by promoting endothelial impairment and coronary microvascular dysfunction. MicroRNAs (miRNAs) have emerged as potential biomarkers and therapeutic targets in various biological processes, including endothelial dysfunction and cardiovascular diseases. However, research on miRNA biomarkers in INOCA patients is sparse. In this study, we examined a panel of circulating miRNAs involved in the regulation of endothelial function in INOCA patients with and without DM. We analyzed miRNA expression using RT-qPCR in a cohort of consecutive INOCA patients undergoing percutaneous coronary intervention. We detected a significant dysregulation of miR-363-5p and miR-92a-3p in INOCA patients with DM compared to those without DM, indicating their role as biomarkers for predicting and monitoring endothelial dysfunction in INOCA patients with DM., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. Prediabetes Increases the Risk of Frailty in Prefrail Older Adults With Hypertension: Beneficial Effects of Metformin.
- Author
-
Santulli G, Visco V, Varzideh F, Guerra G, Kansakar U, Gasperi M, Marro A, Wilson S, Ferrante MNV, Pansini A, Pirone A, Di Lorenzo F, Tartaglia D, Iaccarino G, Macina G, Agyapong ED, Forzano I, Jankauskas SS, Komici K, Ciccarelli M, and Mone P
- Subjects
- Humans, Male, Aged, Female, Insulin Resistance, Frail Elderly, Aged, 80 and over, Cognitive Dysfunction epidemiology, Cognitive Dysfunction prevention & control, Cognitive Dysfunction etiology, Blood Glucose drug effects, Blood Glucose metabolism, Metformin therapeutic use, Prediabetic State drug therapy, Frailty epidemiology, Hypertension drug therapy, Hypertension epidemiology, Hypoglycemic Agents therapeutic use
- Abstract
Background: Prediabetes has garnered increasing attention due to its association with cardiovascular conditions, especially hypertension, which heightens the risk of prefrailty and frailty among older individuals., Methods: We screened elders with prefrail hypertension from March 2021 to January 2023. We assessed the correlation linking cognitive dysfunction (Montreal Cognitive Assessment score), insulin resistance (triglyceride-to-glucose index), and physical impairment (5-meter gait speed). Then, we measured the risk of developing frailty after a 1-year follow-up period, adjusting the outcome using multivariable Cox regression analysis. We also investigated the impact of administering 500 mg of metformin once daily to a subset of frail subjects for an additional 6 months., Results: We assessed the relationship between the triglyceride-to-glucose index and the Montreal Cognitive Assessment score, observing a significant correlation (r, 0.880; P <0.0001). Similarly, we analyzed the association between the triglyceride-to-glucose index and 5-meter gait speed, uncovering a significant link between insulin resistance and physical impairment (r, 0.809; P <0.0001). Prediabetes was found to significantly ( P <0.0001) elevate the risk of frailty development compared with individuals without prediabetes by the end of the 1-year follow-up, a finding confirmed via multivariable analysis with Cox regression. Furthermore, among the subgroup of subjects who developed frailty, those who received metformin exhibited a significant decrease in frailty levels ( P <0.0001)., Conclusions: Insulin resistance and prediabetes play substantial roles in the development of cognitive and physical impairments, highlighting their importance in managing hypertension, even before the onset of frank diabetes. Metformin, a well-established drug for the treatment of diabetes, has shown favorable effects in mitigating frailty., Competing Interests: Disclosures None.
- Published
- 2024
- Full Text
- View/download PDF
11. Exploring the Therapeutic Potential of Bromelain: Applications, Benefits, and Mechanisms.
- Author
-
Kansakar U, Trimarco V, Manzi MV, Cervi E, Mone P, and Santulli G
- Subjects
- Humans, Animals, Fruit chemistry, Bromelains therapeutic use, Bromelains pharmacology, Ananas chemistry
- Abstract
Bromelain is a mixture of proteolytic enzymes primarily extracted from the fruit and stem of the pineapple plant ( Ananas comosus ). It has a long history of traditional medicinal use in various cultures, particularly in Central and South America, where pineapple is native. This systematic review will delve into the history, structure, chemical properties, and medical indications of bromelain. Bromelain was first isolated and described in the late 19th century by researchers in Europe, who identified its proteolytic properties. Since then, bromelain has gained recognition in both traditional and modern medicine for its potential therapeutic effects.
- Published
- 2024
- Full Text
- View/download PDF
12. COVID-19 causes the opening of the mitochondrial permeability transition pore in human endothelial cells.
- Author
-
Gambardella J, Jankauskas SS, Kansakar U, Varzideh F, Avvisato R, and Santulli G
- Subjects
- Humans, SARS-CoV-2, Mitochondria metabolism, Endothelial Cells metabolism, Endothelial Cells virology, Endothelial Cells pathology, Human Umbilical Vein Endothelial Cells metabolism, Mitochondrial Membrane Transport Proteins metabolism, COVID-19 metabolism, Mitochondrial Permeability Transition Pore metabolism
- Published
- 2024
- Full Text
- View/download PDF
13. miR-181c modulates SMAD7 and Parkin in human cardiac fibroblasts: Validation in frail older adults with diabetes and HFpEF.
- Author
-
Avvisato R, Jankauskas SS, Mone P, Kansakar U, Varzideh F, De Gennaro S, Salemme L, Cioppa A, Frullone S, Macina G, Di Mauro M, Tesorio T, Gambardella J, and Santulli G
- Subjects
- Humans, Aged, Male, Female, Frail Elderly, Cells, Cultured, Aged, 80 and over, Stroke Volume, Age Factors, Frailty metabolism, Frailty genetics, Ventricular Function, Left, Signal Transduction, Fibroblasts metabolism, Fibroblasts pathology, Ubiquitin-Protein Ligases metabolism, Ubiquitin-Protein Ligases genetics, MicroRNAs metabolism, MicroRNAs genetics, Heart Failure metabolism, Heart Failure physiopathology, Heart Failure genetics, Heart Failure pathology
- Published
- 2024
- Full Text
- View/download PDF
14. Ketogenic diet improves chromatin remodeling and rescues mitochondrial dysfunction in ischemic heart disease by regulating PGC-1alpha transcription.
- Author
-
Gambardella J, Varzideh F, Jankauskas SS, Kansakar U, Sidoli S, Lombardi A, and Santulli G
- Subjects
- Animals, Transcription, Genetic, Mice, Disease Models, Animal, Male, Humans, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha metabolism, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha genetics, Diet, Ketogenic, Chromatin Assembly and Disassembly, Myocardial Ischemia metabolism, Myocardial Ischemia genetics, Myocardial Ischemia physiopathology, Mitochondria, Heart metabolism, Mitochondria, Heart pathology
- Published
- 2024
- Full Text
- View/download PDF
15. Endothelial Extracellular Vesicles Enriched in microRNA-34a Predict New-Onset Diabetes in Coronavirus Disease 2019 (COVID-19) Patients: Novel Insights for Long COVID Metabolic Sequelae.
- Author
-
Mone P, Jankauskas SS, Manzi MV, Gambardella J, Coppola A, Kansakar U, Izzo R, Fiorentino G, Lombardi A, Varzideh F, Sorriento D, Trimarco B, and Santulli G
- Subjects
- Humans, Post-Acute COVID-19 Syndrome, SARS-CoV-2, Endothelial Cells, Disease Progression, COVID-19 complications, Diabetes Mellitus, MicroRNAs, Hypertension, Dyslipidemias
- Abstract
Emerging evidence indicates that the relationship between coronavirus disease 2019 (COVID-19) and diabetes is 2-fold: 1) it is known that the presence of diabetes and other metabolic alterations poses a considerably high risk to develop a severe COVID-19; 2) patients who survived a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have an increased risk of developing new-onset diabetes. However, the mechanisms underlying this association are mostly unknown, and there are no reliable biomarkers to predict the development of new-onset diabetes. In the present study, we demonstrate that a specific microRNA (miR-34a) contained in circulating extracellular vesicles released by endothelial cells reliably predicts the risk of developing new-onset diabetes in COVID-19. This association was independent of age, sex, body mass index (BMI), hypertension, dyslipidemia, smoking status, and D-dimer. SIGNIFICANCE STATEMENT: We demonstrate for the first time that a specific microRNA (miR-34a) contained in circulating extracellular vesicles released by endothelial cells is able to reliably predict the risk of developing diabetes after having contracted coronavirus disease 2019 (COVID-19). This association was independent of age, sex, body mass index (BMI), hypertension, dyslipidemia, smoking status, and D-dimer. Our findings are also relevant when considering the emerging importance of post-acute sequelae of COVID-19, with systemic manifestations observed even months after viral negativization (long COVID)., (Copyright © 2024 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2024
- Full Text
- View/download PDF
16. Combining choline bitartrate and vitamin B12 ameliorates cognitive impairment in hypertensive elders with cognitive frailty.
- Author
-
Mone P, Trimarco V, Kansakar U, Izzo R, Santulli G, and Trimarco B
- Subjects
- Humans, Aged, Vitamin B 12 therapeutic use, Cognition, Frailty drug therapy, Cognitive Dysfunction drug therapy
- Abstract
Competing Interests: Declaration of Competing Interest BT reports personal fees for speaker bureau, outside the content of the current manuscript, from Malesci, Damor, MSD, and Fidia.
- Published
- 2024
- Full Text
- View/download PDF
17. Interleukin-1 receptor associated kinase 2 is a functional downstream regulator of complement factor D that controls mitochondrial fitness in diabetic cardiomyopathy.
- Author
-
Jankauskas SS, Varzideh F, Mone P, Kansakar U, Di Lorenzo F, Lombardi A, and Santulli G
- Subjects
- Humans, Interleukin-1 Receptor-Associated Kinases, Complement Factor D, Receptors, Interleukin-1, Fatty Acids, Diabetic Cardiomyopathies, Diabetes Mellitus
- Published
- 2024
- Full Text
- View/download PDF
18. Leukocytes and Endothelial Cells Participate in the Pathogenesis of Alzheimer's Disease: Identifying New Biomarkers Mirroring Metabolic Alterations.
- Author
-
Mone P, De Luca A, Kansakar U, and Santulli G
- Subjects
- Humans, Endothelial Cells metabolism, Amyloid beta-Peptides metabolism, Leukocytes metabolism, Biomarkers, Alzheimer Disease pathology
- Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder marked by amyloid-β accumulation, tau dysfunction, and neuroinflammation, involving endothelial cells and leukocytes. The breakdown of the blood-brain barrier allows immune cell infiltration, intensifying inflammation. A decreased ratio of Connexin-37 (Cx37, also known as GJA4: Gap Junction Protein Alpha 4) and Prolyl Hydroxylase Domain-Containing Protein 3 (PHD3, also known as EGLN3: Egl-9 Family Hypoxia Inducible Factor 3), Cx37/PHD3, consistently observed in different AD-related models, may represent a novel potential biomarker of AD, albeit the exact mechanisms underlying this phenomenon, most likely based on gap junction-mediated cellular interaction that modulate the cellular metabolite status, remain to be fully elucidated.
- Published
- 2024
- Full Text
- View/download PDF
19. Functional Role of Taurine in Aging and Cardiovascular Health: An Updated Overview.
- Author
-
Santulli G, Kansakar U, Varzideh F, Mone P, Jankauskas SS, and Lombardi A
- Subjects
- Animals, Humans, Antioxidants pharmacology, Dietary Supplements, Aging, Taurine pharmacology, Taurine metabolism, Heart
- Abstract
Taurine, a naturally occurring sulfur-containing amino acid, has attracted significant attention in recent years due to its potential health benefits. Found in various foods and often used in energy drinks and supplements, taurine has been studied extensively to understand its impact on human physiology. Determining its exact functional roles represents a complex and multifaceted topic. We provide an overview of the scientific literature and present an analysis of the effects of taurine on various aspects of human health, focusing on aging and cardiovascular pathophysiology, but also including athletic performance, metabolic regulation, and neurological function. Additionally, our report summarizes the current recommendations for taurine intake and addresses potential safety concerns. Evidence from both human and animal studies indicates that taurine may have beneficial cardiovascular effects, including blood pressure regulation, improved cardiac fitness, and enhanced vascular health. Its mechanisms of action and antioxidant properties make it also an intriguing candidate for potential anti-aging strategies.
- Published
- 2023
- Full Text
- View/download PDF
20. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.
- Author
-
Santulli G, Varzideh F, Forzano I, Wilson S, Salemme L, de Donato A, Lombardi A, Rainone A, Nunziata L, Jankauskas SS, Tesorio T, Guerra G, Kansakar U, and Mone P
- Subjects
- Humans, Aged, Hypoglycemic Agents pharmacology, Sodium-Glucose Transporter 2 pharmacology, Clinical Relevance, Kidney, Glucose, Benzhydryl Compounds pharmacology, Benzhydryl Compounds therapeutic use, Sodium, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Diabetes Mellitus, Type 2, Frailty
- Abstract
SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) act by increasing glycosuria, thereby reducing glycemia. These drugs are critical to reach and keep glycemic control, a crucial feature, especially in patients with comorbidities, like frail individuals. Several studies evaluated the effects of SGLT2-inhibitors in different settings beyond diabetes, revealing that they are actually pleiotropic drugs. We recently evidenced the favorable effects of SGLT2-inhibition on physical and cognitive impairment in frail older adults with diabetes and hypertension. In the present overview, we summarize the latest clinical and preclinical studies exploring the main effects of SGLT2-inhibitors on kidney and heart, emphasizing their potential beneficial actions in frailty., Competing Interests: Disclosures None.
- Published
- 2023
- Full Text
- View/download PDF
21. Ketone Bodies Rescue Mitochondrial Dysfunction Via Epigenetic Remodeling.
- Author
-
Gambardella J, Jankauskas SS, Kansakar U, Varzideh F, Avvisato R, Prevete N, Sidoli S, Mone P, Wang X, Lombardi A, and Santulli G
- Abstract
Ischemic cardiac disease is a major cause of mortality worldwide. However, the exact molecular processes underlying this disorder are not fully known. This study includes a comprehensive and coordinated set of in vivo and in vitro experiments using human cardiac specimens from patients with postischemic heart failure (HF) and healthy control subjects, a murine model of HF, and cellular systems. These approaches identified for the first time a specific pattern of maladaptive chromatin remodeling, namely a double methylation of histone 3 at lysine 27 and a single methylation at lysine 36 (H3_K27me2K36me1) consistently induced by ischemic injury in all these settings: human HF; murine HF; and in vitro models. Mechanistically, this work demonstrates that this histone modification mediates the ischemia-induced transcriptional repression of PPARG coactivator 1α (PGC1α), master regulator of mitochondrial function and biogenesis. Intriguingly, both the augmented H3_K27me2K36me1 and the mitochondrial dysfunction ensued by PGC1α down-regulation were significantly attenuated by the treatment with β-hydroxybutyrate, the most abundant ketone body in humans, revealing a novel pathway coupling metabolism to gene expression. Taken together, these findings establish maladaptive chromatin remodeling as a key mechanism in postischemic heart injury, functionally modulated by ketone bodies., Competing Interests: Prof Santulli has received support in part from the National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (NHLBI: R01-HL164772, R01-HL159062, R01-HL146691, T32-HL144456), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: R01-DK123259, R01-DK033823), National Center for Advancing Translational Sciences (NCATS: UL1-TR002556-06, UM1-TR004400) to Dr Santulli, from the Diabetes Action Research and Education Foundation (to Dr Santulli), and from the Monique Weill-Caulier and Irma T. Hirschl Trusts (to Dr Santulli). Dr Gambardella has received support from a postdoctoral fellowship of the American Heart Association (AHA-20POST35211151). Dr Jankauskas has received support from a postdoctoral fellowship of the American Heart Association (AHA-21POST836407). Dr Kansakar has received support from a postdoctoral fellowship of the American Heart Association (AHA-23POST1026190). Dr Varzideh has received support from a postdoctoral fellowship of the American Heart Association (AHA-22POST915561). Dr Sidoli has received support from the Leukemia Research Foundation (Hollis Brownstein New Investigator Research Grant), Relay Therapeutics, Deerfield (Xseed award), Merck, AFAR (Sagol Network GerOmics award), and the NIH Office of the Director (1S10-OD030286-01). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
22. SGLT2 inhibitors: an evidence-based update on cardiovascular implications.
- Author
-
Forzano I, Wilson S, Lombardi A, Jankauskas SS, Kansakar U, Mone P, Varzideh F, and Santulli G
- Subjects
- Humans, Animals, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Cardiovascular Diseases drug therapy, Diabetes Mellitus, Type 2 drug therapy, Randomized Controlled Trials as Topic, Hypoglycemic Agents pharmacology, Hypoglycemic Agents adverse effects
- Abstract
Introduction: Sodium Glucose co-Transporter 2 (SGLT2) inhibitors (also known as 'gliflozins') represent a cornerstone to treat diabetes mellitus. Moreover, recent randomized clinical trials have demonstrated important cardioprotective effects of gliflozins, independent of the presence of diabetes. Herein, we summarize the recent therapeutic progress in the cardiovascular field obtained with SGLT2 inhibitors., Area Covered: We critically examine the rationale and results of recent clinical studies examining the effects of SGLT2 inhibitors on cardiovascular outcomes, along with a brief overview of the main ongoing trials that have been designed in order to answer the many pending questions in the field of gliflozins and cardiovascular disease., Expert Opinion: The favorable results of several clinical trials have broadened the therapeutic scenario for SGLT2 inhibitors, opening, at the same time, new challenges. Additionally, recent preclinical findings have evidenced off-target effects of SGLT2 inhibitors.
- Published
- 2023
- Full Text
- View/download PDF
23. miR-181c targets Parkin and SMAD7 in human cardiac fibroblasts: Validation of differential microRNA expression in patients with diabetes and heart failure with preserved ejection fraction.
- Author
-
Jankauskas SS, Mone P, Avvisato R, Varzideh F, De Gennaro S, Salemme L, Macina G, Kansakar U, Cioppa A, Frullone S, Gambardella J, Di Mauro M, Tesorio T, and Santulli G
- Subjects
- Humans, Aged, Stroke Volume physiology, Fibrosis, Fibroblasts metabolism, Ubiquitin-Protein Ligases metabolism, Smad7 Protein genetics, Smad7 Protein metabolism, Heart Failure genetics, Heart Failure metabolism, Diabetes Mellitus, MicroRNAs genetics, MicroRNAs metabolism
- Abstract
Background: Cardiac fibrosis represents a key element in the pathophysiology of heart failure with preserved ejection fraction (HFpEF), a condition highly prevalent amongst geriatric patients, especially if diabetic. The microRNA 181c (miR-181c) has been shown to be associated with the response to exercise training in HFpEF patients and has been also linked to diabetic cardiovascular complications. However, the underlying mechanisms have not been fully elucidated., Objective: To measure circulating miR-181c in elderly patients with HFpEF and diabetes mellitus (DM) and identify gene targets pathophysiologically relevant in HFpEF., Methods: We quantified circulating miR-181c in frail older adults with a confirmed diagnosis of HFpEF and DM, and, as control, we enrolled age-matched subjects without HFpEF and without DM. We validated in human cardiac fibroblasts the molecular mechanisms linking miR-181c to a pro-fibrotic response., Results: 51 frail patients were included :34 patients with DM and HFpEF and 17 age-matched controls. We observed that miR-181c was significantly upregulated (p < 0.0001) in HFpEF patients vs controls. We confirmed in vitro that miR-181c is targeting PRKN and SMAD7., Conclusions: We demonstrate that miR-181c levels are significantly increased in frail elderly adults with DM and HFpEF and that miR-181c targets PRKN and SMAD7 in human cardiac fibroblasts., Competing Interests: Conflicts of interest The authors declare no conflicts of interest., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Correction: L-Arginine in diabetes: clinical and preclinical evidence.
- Author
-
Forzano I, Avvisato R, Varzideh F, Jankauskas SS, Cioppa A, Mone P, Salemme L, Kansakar U, Tesorio T, Trimarco V, and Santulli G
- Published
- 2023
- Full Text
- View/download PDF
25. Molecular Mechanisms Underlying Pluripotency and Self-Renewal of Embryonic Stem Cells.
- Author
-
Varzideh F, Gambardella J, Kansakar U, Jankauskas SS, and Santulli G
- Subjects
- Humans, Animals, Mice, Blastocyst, Signal Transduction, Transcription Factors metabolism, Cell Differentiation, Embryonic Stem Cells, Human Embryonic Stem Cells metabolism
- Abstract
Embryonic stem cells (ESCs) are derived from the inner cell mass (ICM) of the blastocyst. ESCs have two distinctive properties: ability to proliferate indefinitely, a feature referred as "self-renewal", and to differentiate into different cell types, a peculiar characteristic known as "pluripotency". Self-renewal and pluripotency of ESCs are finely orchestrated by precise external and internal networks including epigenetic modifications, transcription factors, signaling pathways, and histone modifications. In this systematic review, we examine the main molecular mechanisms that sustain self-renewal and pluripotency in both murine and human ESCs. Moreover, we discuss the latest literature on human naïve pluripotency.
- Published
- 2023
- Full Text
- View/download PDF
26. Choline Supplementation Improves Cognitive Performance in Frail Hypertensive Patients: Novel Insights on Endothelial Function from the INTERVENTIONIST Study.
- Author
-
Mone P, Kansakar U, Lucariello A, Marro A, Pansini A, Varzideh F, Nittolo G, De Angelis L, Trimarco V, Martinelli G, De Luca A, and Santulli G
- Published
- 2023
- Full Text
- View/download PDF
27. L-Arginine in diabetes: clinical and preclinical evidence.
- Author
-
Forzano I, Avvisato R, Varzideh F, Jankauskas SS, Cioppa A, Mone P, Salemme L, Kansakar U, Tesorio T, Trimarco V, and Santulli G
- Subjects
- Animals, Humans, Arginine metabolism, Nitric Oxide metabolism, Diabetes Mellitus diagnosis, Diabetes Mellitus drug therapy, Glucose Intolerance
- Abstract
L-Arginine (L-Arg), is a semi-essential amino acid involved in the formation of nitric oxide. The functional relevance of L-Arg in diabetes mellitus has been evaluated both in animal models and in human subjects. In the literature there are several lines of evidence indicating that L-Arg has beneficial effects in diabetes and numerous studies advocate its administration to attenuate glucose intolerance in diabetic patients. Here we present a comprehensive overview of the main studies exploring the effects of L-Arg in diabetes, including preclinical and clinical reports on this topic., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
28. miR-4432 Targets FGFBP1 in Human Endothelial Cells.
- Author
-
Avvisato R, Mone P, Jankauskas SS, Varzideh F, Kansakar U, Gambardella J, De Luca A, Matarese A, and Santulli G
- Abstract
MicroRNAs (miRs) are small non-coding RNAs that modulate the expression of several target genes. Fibroblast growth factor binding protein 1 (FGFBP1) has been associated with endothelial dysfunction at the level of the blood-brain barrier (BBB). However, the underlying mechanisms are mostly unknown and there are no studies investigating the relationship between miRs and FGFBP1. Thus, the overarching aim of the present study was to identify and validate which miR can specifically target FGFBP1 in human brain microvascular endothelial cells, which represent the best in vitro model of the BBB. We were able to identify and validate miR-4432 as a fundamental modulator of FGFBP1 and we demonstrated that miR-4432 significantly reduces mitochondrial oxidative stress, a well-established pathophysiological hallmark of hypertension.
- Published
- 2023
- Full Text
- View/download PDF
29. Choline supplements: An update.
- Author
-
Kansakar U, Trimarco V, Mone P, Varzideh F, Lombardi A, and Santulli G
- Subjects
- Acetylcholine, Dietary Supplements, Cytidine Diphosphate Choline, Choline pharmacology, Glycerylphosphorylcholine pharmacology
- Abstract
In this comprehensive review, we examine the main preclinical and clinical investigations assessing the effects of different forms of choline supplementation currently available, including choline alfoscerate (C
8 H20 NO6 P), also known as alpha-glycerophosphocholine (α-GPC, or GPC), choline bitartrate, lecithin, and citicoline, which are cholinergic compounds and precursors of acetylcholine. Extensively used as food supplements, they have been shown to represent an effective strategy for boosting memory and enhancing cognitive function., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Kansakar, Trimarco, Mone, Varzideh, Lombardi and Santulli.)- Published
- 2023
- Full Text
- View/download PDF
30. Sortilin and hypertension.
- Author
-
Avvisato R, Jankauskas SS, Varzideh F, Kansakar U, Mone P, and Santulli G
- Subjects
- Humans, Vascular Calcification metabolism, Adaptor Proteins, Vesicular Transport metabolism, Glycoproteins metabolism, Hypertension metabolism
- Abstract
Purpose of Review: The current review aims to present the latest scientific updates on the role of Sortilin in the pathophysiology of hypertension., Recent Findings: The main focus of this systematic overview is on the functional contribution of Sortilin to the pathogenesis of hypertension. Sortilin is a glycoprotein mostly known for its actions as a trafficking molecule directing proteins to specific secretory or endocytic compartments of the cell. Emerging evidence indicates that Sortilin is associated with pathological conditions, including inflammation, arteriosclerosis, dyslipidemia, insulin resistance, and vascular calcification. Most recently, Sortilin has been shown to finely control endothelial function and to drive hypertension by modulating sphingolipid/ceramide homeostasis and by triggering oxidative stress., Summary: The latest findings linking Sortilin and hypertension that are herein discussed can inspire novel areas of research which could eventually lead to the discovery of new therapeutic strategies in cardiovascular medicine., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. Targeting cardiovascular and metabolic disorders through annual nationwide screening and lifestyle intervention: insights from a cohort of 5 819 041 subjects with a 4-year follow-up.
- Author
-
Santulli G, Jankauskas SS, Varzideh F, Mone P, and Kansakar U
- Subjects
- Humans, Risk Factors, Follow-Up Studies, Obesity, Heart Disease Risk Factors, Life Style, Cardiovascular Diseases prevention & control, Metabolic Diseases
- Abstract
Competing Interests: Conflict of interest: None declared.
- Published
- 2023
- Full Text
- View/download PDF
32. COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells.
- Author
-
Jankauskas SS, Kansakar U, Sardu C, Varzideh F, Avvisato R, Wang X, Matarese A, Marfella R, Ziosi M, Gambardella J, and Santulli G
- Abstract
Oxidative stress and endothelial dysfunction have been shown to play crucial roles in the pathophysiology of COVID-19 (coronavirus disease 2019). On these grounds, we sought to investigate the impact of COVID-19 on lipid peroxidation and ferroptosis in human endothelial cells. We hypothesized that oxidative stress and lipid peroxidation induced by COVID-19 in endothelial cells could be linked to the disease outcome. Thus, we collected serum from COVID-19 patients on hospital admission, and we incubated these sera with human endothelial cells, comparing the effects on the generation of reactive oxygen species (ROS) and lipid peroxidation between patients who survived and patients who did not survive. We found that the serum from non-survivors significantly increased lipid peroxidation. Moreover, serum from non-survivors markedly regulated the expression levels of the main markers of ferroptosis, including GPX4, SLC7A11, FTH1, and SAT1, a response that was rescued by silencing TNFR1 on endothelial cells. Taken together, our data indicate that serum from patients who did not survive COVID-19 triggers lipid peroxidation in human endothelial cells.
- Published
- 2023
- Full Text
- View/download PDF
33. Exosomal miR-145 and miR-885 Regulate Thrombosis in COVID-19.
- Author
-
Gambardella J, Kansakar U, Sardu C, Messina V, Jankauskas SS, Marfella R, Maggi P, Wang X, Mone P, Paolisso G, Sorriento D, and Santulli G
- Subjects
- Humans, Endothelial Cells, SARS-CoV-2, COVID-19 complications, MicroRNAs genetics, MicroRNAs metabolism, Post-Acute COVID-19 Syndrome genetics, Post-Acute COVID-19 Syndrome metabolism, Thrombosis genetics, Thrombosis metabolism, Thrombosis virology, Exosomes metabolism
- Abstract
We hypothesized that exosomal microRNAs could be implied in the pathogenesis of thromboembolic complications in coronavirus disease 2019 (COVID-19). We isolated circulating exosomes from patients with COVID-19, and then we divided our population in two arms based on the D-dimer level on hospital admission. We observed that exosomal miR-145 and miR-885 significantly correlate with D-dimer levels. Moreover, we demonstrate that human endothelial cells express the main cofactors needed for the internalization of the "Severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2), including angiotensin converting enzyme 2, transmembrane protease serine 2, and CD-147. Interestingly, human endothelial cells treated with serum from COVID-19 patients release significantly less miR-145 and miR-885, exhibit increased apoptosis, and display significantly impaired angiogenetic properties compared with cells treated with non-COVID-19 serum. Taken together, our data indicate that exosomal miR-145 and miR-885 are essential in modulating thromboembolic events in COVID-19. SIGNIFICANCE STATEMENT: This work demonstrates for the first time that two specific microRNAs (namely miR-145 and miR-885) contained in circulating exosomes are functionally involved in thromboembolic events in COVID-19. These findings are especially relevant to the general audience when considering the emerging prominence of post-acute sequelae of COVID-19 systemic manifestations known as Long COVID., (Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2023
- Full Text
- View/download PDF
34. Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes.
- Author
-
Mone P, Lombardi A, Kansakar U, Varzideh F, Jankauskas SS, Pansini A, Marzocco S, De Gennaro S, Famiglietti M, Macina G, Frullone S, and Santulli G
- Subjects
- Humans, Aged, Sodium-Glucose Transporter 2, Stroke Volume, Biomarkers, MicroRNAs genetics, Heart Failure, Diabetes Mellitus, Metformin pharmacology, Metformin therapeutic use, Vascular Diseases, Insulins metabolism, Insulins therapeutic use
- Abstract
Endothelial dysfunction represents a key mechanism underlying heart failure with preserved ejection fraction (HFpEF), diabetes mellitus (DM), and frailty. However, reliable biomarkers to monitor endothelial dysfunction in these patients are lacking. In this study, we evaluated the expression of a panel of circulating microRNAs (miRs) involved in the regulation of endothelial function in a population of frail older adults with HFpEF and DM treated for 3 months with empagliflozin, metformin, or insulin. We identified a distinctive pattern of miRs that were significantly regulated in HFpEF patients compared to healthy controls and to HFpEF patients treated with the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin. Three miRs were significantly downregulated (miR-126, miR-342-3p, and miR-638) and two were significantly upregulated (miR-21 and miR-92) in HFpEF patients compared to healthy controls. Strikingly, two of these miRs (miR-21 and miR-92) were significantly reduced in HFpEF patients after the 3-month treatment with empagliflozin, whereas no significant differences in the profile of endothelial miRs were detected in patients treated with metformin or insulin. Taken together, our findings demonstrate for the first time that specific circulating miRs involved in the regulation of endothelial function are significantly regulated in frail HFpEF patients with DM and in response to SGLT2 inhibition. SIGNIFICANCE STATEMENT: We have identified a novel microRNA signature functionally involved in the regulation of endothelial function that is significantly regulated in frail patients with HFpEF and diabetes. Moreover, the treatment with the SGLT2 inhibitor empagliflozin caused a modification of some of these microRNAs in a direction that was opposite to what observed in HFpEF patients, indicating a rescue of endothelial function. Our findings are relevant for clinical practice inasmuch as we were able to establish novel biomarkers of disease and response to therapy., (Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2023
- Full Text
- View/download PDF
35. Aprocitentan: New insights.
- Author
-
Varzideh F, Kansakar U, Jankauskas SS, and Santulli G
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
36. Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure.
- Author
-
Forzano I, Mone P, Mottola G, Kansakar U, Salemme L, De Luca A, Tesorio T, Varzideh F, and Santulli G
- Abstract
Current therapeutic strategies for acute heart failure (AHF) are based on traditional inotropic agents that are often associated with untoward effects; therefore, finding new effective approaches with a safer profile is dramatically needed. Istaroxime is a novel compound, chemically unrelated to cardiac glycosides, that is currently being studied for the treatment of AHF. Its effects are essentially related to its inotropic and lusitropic positive properties exerted through a dual mechanism of action: activation of the sarcoplasmic reticulum Ca
2+ ATPase isoform 2a (SERCA2a) and inhibition of the Na+ /K+ -ATPase (NKA) activity. The advantages of istaroxime over the available inotropic agents include its lower arrhythmogenic action combined with its capability of increasing systolic blood pressure without augmenting heart rate. However, it has a limited half-life (1 hour) and is associated with adverse effects including pain at the injection site and gastrointestinal issues. Herein, we describe the main mechanism of action of istaroxime and we present a systematic overview of both clinical and preclinical trials testing this drug, underlining the latest insights regarding its adoption in clinical practice for AHF.- Published
- 2022
- Full Text
- View/download PDF
37. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
- Author
-
Forzano I, Mone P, Varzideh F, Jankauskas SS, Kansakar U, De Luca A, and Santulli G
- Subjects
- Humans, Blood Pressure, Cytochrome P-450 CYP11B2, Mineralocorticoid Receptor Antagonists, Enzyme Inhibitors, Aldosterone, Hypertension
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
38. miR-142 Targets TIM-1 in Human Endothelial Cells: Potential Implications for Stroke, COVID-19, Zika, Ebola, Dengue, and Other Viral Infections.
- Author
-
Kansakar U, Gambardella J, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Matarese A, and Santulli G
- Subjects
- Angiotensin-Converting Enzyme 2, COVID-19, Dengue, Endothelial Cells metabolism, Hemorrhagic Fever, Ebola, Humans, Immunoglobulins, Mucins, Neuropilin-1 genetics, Peptidyl-Dipeptidase A, SARS-CoV-2, Stroke, Zika Virus, Zika Virus Infection, Endothelial Cells pathology, Hepatitis A Virus Cellular Receptor 1 metabolism, MicroRNAs genetics
- Abstract
T-cell immunoglobulin and mucin domain 1 (TIM-1) has been recently identified as one of the factors involved in the internalization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human cells, in addition to angiotensin-converting enzyme 2 (ACE2), transmembrane serine protease 2 (TMPRSS2), neuropilin-1, and others. We hypothesized that specific microRNAs could target TIM-1, with potential implications for the management of patients suffering from coronavirus disease 2019 (COVID-19). By combining bioinformatic analyses and functional assays, we identified miR-142 as a specific regulator of TIM-1 transcription. Since TIM-1 has been implicated in the regulation of endothelial function at the level of the blood-brain barrier (BBB) and its levels have been shown to be associated with stroke and cerebral ischemia-reperfusion injury, we validated miR-142 as a functional modulator of TIM-1 in human brain microvascular endothelial cells (hBMECs). Taken together, our results indicate that miR-142 targets TIM-1, representing a novel strategy against cerebrovascular disorders, as well as systemic complications of SARS-CoV-2 and other viral infections.
- Published
- 2022
- Full Text
- View/download PDF
39. Parkin Controls Cardiac Function in Obesity by Regulating Mitochondrial Calcium Uptake.
- Author
-
Jankauskas S, Kansakar U, De Donato A, Mone P, Varzideh F, and Santulli G
- Abstract
Competing Interests: Dr Santulli’s laboratory is supported in part by the National Institutes of Health (grants R01-HL159062, R01-DK123259, R01-DK033823, R01-HL146691, and T32-HL144456 to Dr Santulli), by the Irma T. Hirschl and Monique Weill-Caulier Trusts, and by the Diabetes Action Research and Education Foundation. Drs Jankauskas and Varzideh hold postdoctoral fellowships from the American Heart Association (AHA-21POST836407 and AHA-22POST915561, respectively). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Published
- 2022
- Full Text
- View/download PDF
40. Functional role of miR-34a in diabetes and frailty.
- Author
-
Mone P, de Donato A, Varzideh F, Kansakar U, Jankauskas SS, Pansini A, and Santulli G
- Abstract
Emerging evidence has shown that microRNAs (miRNAs) play critical role in the pathogenesis of several disorders. In the present minireview, we focus our attention on the functional role of a specific miRNA, namely miR-34a, in the pathophysiology of frailty and diabetes mellitus. Based on the current literature, we speculate that this miRNA may serve as a potential biomarker of frailty in diabetic older adults. Additionally, its actions on oxidative stress might represent a druggable target to obtain new potentials treatments., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Mone, de Donato, Varzideh, Kansakar, Jankauskas, Pansini and Santulli.)
- Published
- 2022
- Full Text
- View/download PDF
41. Cardiac Remodeling After Myocardial Infarction: Functional Contribution of microRNAs to Inflammation and Fibrosis.
- Author
-
Varzideh F, Kansakar U, Donkor K, Wilson S, Jankauskas SS, Mone P, Wang X, Lombardi A, and Santulli G
- Abstract
After an ischemic injury, the heart undergoes a complex process of structural and functional remodeling that involves several steps, including inflammatory and fibrotic responses. In this review, we are focusing on the contribution of microRNAs in the regulation of inflammation and fibrosis after myocardial infarction. We summarize the most updated studies exploring the interactions between microRNAs and key regulators of inflammation and fibroblast activation and we discuss the recent discoveries, including clinical applications, in these rapidly advancing fields., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Varzideh, Kansakar, Donkor, Wilson, Jankauskas, Mone, Wang, Lombardi and Santulli.)
- Published
- 2022
- Full Text
- View/download PDF
42. L-Arginine Improves Cognitive Impairment in Hypertensive Frail Older Adults.
- Author
-
Mone P, Pansini A, Jankauskas SS, Varzideh F, Kansakar U, Lombardi A, Trimarco V, Frullone S, and Santulli G
- Abstract
Cognitive impairment is a prevailing event in hypertensive patients and in frail older adults. Endothelial dysfunction has been shown to underlie both hypertension and cognitive dysfunction. Our hypothesis is that L-Arginine, which is known to ameliorate endothelial dysfunction, could counteract cognitive impairment in a high-risk population of hypertensive frail older adults. We designed a clinical trial to verify the effects of 4-weeks oral supplementation of L-Arginine on global cognitive function of hypertensive frail older patients. The study was successfully completed by 35 frail hypertensive elderly patients assigned to L-Arginine and 37 assigned to placebo. At follow-up, we found a significant difference in the Montreal Cognitive Assessment (MoCA) test score between the L-Arginine treated group and placebo ( p : 0.0178). Moreover, we demonstrated that L-Arginine significantly attenuates Angiotensin II-induced mitochondrial oxidative stress in human endothelial cells. In conclusion, our findings indicate for the first time that oral L-Arginine supplementation significantly improves cognitive impairment in frail hypertensive older adults., Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT04962841., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Mone, Pansini, Jankauskas, Varzideh, Kansakar, Lombardi, Trimarco, Frullone and Santulli.)
- Published
- 2022
- Full Text
- View/download PDF
43. Epidemiology of obstructive sleep apnea: What is the contribution of hypertension and arterial stiffness?
- Author
-
Mone P, Kansakar U, Varzideh F, Boccalone E, Lombardi A, Pansini A, and Santulli G
- Subjects
- Humans, Polysomnography, Hypertension epidemiology, Sleep Apnea, Obstructive complications, Sleep Apnea, Obstructive epidemiology, Vascular Stiffness
- Published
- 2022
- Full Text
- View/download PDF
44. Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients.
- Author
-
Mone P, Varzideh F, Kansakar U, Infante C, Lombardi A, de Donato A, Frullone S, and Santulli G
- Subjects
- Animals, Glucose, Humans, Lipid Metabolism, Triglycerides, Diabetes Mellitus, Fatty Acids, Omega-3 metabolism, Fatty Acids, Omega-3 therapeutic use
- Abstract
Omega 3 polyunsaturated fatty acids (n-3 PUFA) are known to have beneficial effects on cardiovascular and metabolic health. However, whether different sources of n-3 PUFA, for instance fatty fish vs vegetable oils, could elicit different effects on glucose and lipid metabolism, remains to be determined. Herein we examine recent findings showing that while a plant-based n-3 PUFA supplementation for six months can reduce fasting blood glucose, marine-based n-3 PUFA can instead reduce serum levels of triglycerides. We also discuss the potential molecular mechanisms that could underlie these different effects on the regulation of glycolipid metabolism., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
45. Functional Role of microRNAs in Regulating Cardiomyocyte Death.
- Author
-
Kansakar U, Varzideh F, Mone P, Jankauskas SS, and Santulli G
- Subjects
- Apoptosis genetics, Autophagy genetics, Humans, Myocytes, Cardiac metabolism, MicroRNAs genetics, MicroRNAs metabolism, Myocardial Infarction genetics, Myocardial Infarction metabolism
- Abstract
microRNAs (miRNA, miRs) play crucial roles in cardiovascular disease regulating numerous processes, including inflammation, cell proliferation, angiogenesis, and cell death. Herein, we present an updated and comprehensive overview of the functional involvement of miRs in the regulation of cardiomyocyte death, a central event in acute myocardial infarction, ischemia/reperfusion, and heart failure. Specifically, in this systematic review we are focusing on necrosis, apoptosis, and autophagy.
- Published
- 2022
- Full Text
- View/download PDF
46. Diabetes and restenosis.
- Author
-
Wilson S, Mone P, Kansakar U, Jankauskas SS, Donkor K, Adebayo A, Varzideh F, Eacobacci M, Gambardella J, Lombardi A, and Santulli G
- Subjects
- Coronary Angiography adverse effects, Humans, Stents adverse effects, Treatment Outcome, Angioplasty, Balloon, Coronary adverse effects, Coronary Restenosis epidemiology, Coronary Restenosis etiology, Diabetes Mellitus diagnosis, Diabetes Mellitus epidemiology, Diabetes Mellitus etiology
- Abstract
Restenosis, defined as the re-narrowing of an arterial lumen after revascularization, represents an increasingly important issue in clinical practice. Indeed, as the number of stent placements has risen to an estimate that exceeds 3 million annually worldwide, revascularization procedures have become much more common. Several investigators have demonstrated that vessels in patients with diabetes mellitus have an increased risk restenosis. Here we present a systematic overview of the effects of diabetes on in-stent restenosis. Current classification and updated epidemiology of restenosis are discussed, alongside the main mechanisms underlying the pathophysiology of this event. Then, we summarize the clinical presentation of restenosis, emphasizing the importance of glycemic control in diabetic patients. Indeed, in diabetic patients who underwent revascularization procedures a proper glycemic control remains imperative., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
47. Sortilin drives hypertension by modulating sphingolipid/ceramide homeostasis and by triggering oxidative stress.
- Author
-
Varzideh F, Jankauskas SS, Kansakar U, Mone P, Gambardella J, and Santulli G
- Subjects
- Adaptor Proteins, Vesicular Transport, Endothelial Cells metabolism, Homeostasis, Humans, Lysophospholipids metabolism, Oxidative Stress, Sphingolipids, Sphingosine metabolism, Ceramides metabolism, Hypertension genetics, Hypertension metabolism
- Abstract
Sortilin is a glycoprotein mainly known for its role as a trafficking molecule directing proteins to specific secretory or endocytic compartments of the cell. Its actual contribution to essential hypertension has remained hitherto elusive. Combining top-notch in vivo, ex vivo, and in vitro approaches to clinical investigations, Di Pietro et al. explored the signaling pathway evoked by sortilin in endothelial cells and report on such exploration in this issue of the JCI. The researchers identified circulating sortilin as a biomarker associated with high blood pressure. Mechanistically, they demonstrate that sortilin altered sphingolipid/ceramide homeostasis, initiating a signaling cascade that, from sphingosine-1-phosphate (S1P), leads to the augmented production of reactive oxygen species. Herein, we discuss the main implications of these findings, and we anticipate some of the potential avenues of investigation prompted by this discovery, which could eventually lead to treatments for cardiometabolic disorders.
- Published
- 2022
- Full Text
- View/download PDF
48. Heart failure in diabetes.
- Author
-
Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, Gambardella J, and Santulli G
- Subjects
- Diabetic Cardiomyopathies etiology, Heart Failure etiology, Humans, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 2 complications, Diabetic Cardiomyopathies physiopathology, Heart Failure physiopathology
- Abstract
Heart failure and cardiovascular disorders represent the leading cause of death in diabetic patients. Here we present a systematic review of the main mechanisms underlying the development of diabetic cardiomyopathy. We also provide an excursus on the relative contribution of cardiomyocytes, fibroblasts, endothelial and smooth muscle cells to the pathophysiology of heart failure in diabetes. After having described the preclinical tools currently available to dissect the mechanisms of this complex disease, we conclude with a section on the most recent updates of the literature on clinical management., Competing Interests: Declaration of competing interest Nothing to declare., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
49. l-Arginine and COVID-19: An Update.
- Author
-
Adebayo A, Varzideh F, Wilson S, Gambardella J, Eacobacci M, Jankauskas SS, Donkor K, Kansakar U, Trimarco V, Mone P, Lombardi A, and Santulli G
- Subjects
- Animals, Arginine therapeutic use, COVID-19 immunology, COVID-19 virology, Endothelial Cells drug effects, Endothelial Cells immunology, Endothelial Cells virology, Host-Pathogen Interactions, Humans, Immune System drug effects, Immune System immunology, Immune System virology, Nitric Oxide metabolism, SARS-CoV-2 immunology, COVID-19 Drug Treatment, Arginine metabolism, COVID-19 metabolism, Endothelial Cells metabolism, Immune System metabolism, SARS-CoV-2 pathogenicity
- Abstract
l-Arginine is involved in many different biological processes and recent reports indicate that it could also play a crucial role in the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein, we present an updated systematic overview of the current evidence on the functional contribution of L-Arginine in COVID-19, describing its actions on endothelial cells and the immune system and discussing its potential as a therapeutic tool, emerged from recent clinical experimentations.
- Published
- 2021
- Full Text
- View/download PDF
50. Ion-Selective Membrane-Coated Graphene-Hexagonal Boron Nitride Heterostructures for Field-Effect Ion Sensing.
- Author
-
Hasan N, Kansakar U, Sherer E, DeCoster MA, and Radadia AD
- Abstract
An intrinsic ion sensitivity exceeding the Nernst-Boltzmann limit and an sp
2 -hybridized carbon structure make graphene a promising channel material for realizing ion-sensitive field-effect transistors with a stable solid-liquid interface under biased conditions in buffered salt solutions. Here, we examine the performance of graphene field-effect transistors coated with ion-selective membranes as a tool to selectively detect changes in concentrations of Ca2+ , K+ , and Na+ in individual salt solutions as well as in buffered Locke's solution. Both the shift in the Dirac point and transconductance could be measured as a function of ion concentration with repeatability exceeding 99.5% and reproducibility exceeding 98% over 60 days. However, an enhancement of selectivity, by about an order magnitude or more, was observed using transconductance as the indicator when compared to Dirac voltage, which is the only factor reported to date. Fabricating a hexagonal boron nitride multilayer between graphene and oxide further increased the ion sensitivity and selectivity of transconductance. These findings incite investigating ion sensitivity of transconductance in alternative architectures as well as urge the exploration of graphene transistor arrays for biomedical applications., Competing Interests: The authors declare no competing financial interest., (© 2021 The Authors. Published by American Chemical Society.)- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.